Last reviewed · How we verify
Tripterygium
At a glance
| Generic name | Tripterygium |
|---|---|
| Sponsor | Nanjing University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy (NA)
- Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA (PHASE4)
- Efficacy and Safety of Colquhounia Root Tablet in Patients With Rheumatoid Arthritis (PHASE4)
- Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis (PHASE2, PHASE3)
- Optimal MTX Dose With Folic Acid Randomized Case-control Trial (PHASE4)
- Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis
- Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis (NA)
- Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tripterygium CI brief — competitive landscape report
- Tripterygium updates RSS · CI watch RSS
- Nanjing University School of Medicine portfolio CI